We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Phoqus | LSE:PQS | London | Ordinary Share | GB00B0M4CD64 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number : 5941W
Phoqus Pharmaceuticals PLC
12 June 2008
Result of AGM
West Malling, UK, 12 June 2008: Phoqus Pharmaceuticals plc (AIM: PQS) ("Phoqus" or the "Company"), the speciality pharmaceutical
company, announces that at the Annual General Meeting of earlier today, all of the resolutions were duly passed.
Enquiries:
Phoqus Pharmaceuticals Tel: 01732 870227
Suzanne Smith, Company Secretary
Nomura Code Securities Limited Tel: 020 7776 1200
Phil Walker
About Phoqus Pharmaceuticals
Phoqus Pharmaceuticals is a speciality pharmaceutical company that aims to develop differentiated products for use in high value,
specialist indications. Its first product candidate is Chronocort®, a novel physiological cortisol replacement therapy in development for
the treatment of patients with congenital adrenal hyperplasia and Addison's disease.
Further background on the Company can be found at www.phoqus.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMBXGDLUXBGGID
1 Year Phoqus Chart |
1 Month Phoqus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
